以下文章来源于E药资本界，作者CM10医药研究中心明明有多款拿得出手的重磅产品，市场对和黄医药却没那么买账？资深分析师：尧 今编审：苏 叶投资有时很魔幻，充满认知张力。比如在港股创新药板块，和黄医药的境遇便一度令投资者费解。作为一家风险可控的企业，它手握国产“替尼三将”（呋喹替尼、赛沃替尼、索凡替尼），核心产品呋喹替尼、赛沃替尼国内市占率稳居第一，账上趴着8亿美元现金（超50亿元），是港股...
Source Link以下文章来源于E药资本界，作者CM10医药研究中心明明有多款拿得出手的重磅产品，市场对和黄医药却没那么买账？资深分析师：尧 今编审：苏 叶投资有时很魔幻，充满认知张力。比如在港股创新药板块，和黄医药的境遇便一度令投资者费解。作为一家风险可控的企业，它手握国产“替尼三将”（呋喹替尼、赛沃替尼、索凡替尼），核心产品呋喹替尼、赛沃替尼国内市占率稳居第一，账上趴着8亿美元现金（超50亿元），是港股...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.